| Identification | Back Directory | [Name]
L-Serine, 2-methyl-N-[[3-[(1E)-2-(2-methyl[1,1'-biphenyl]-3-yl)ethenyl]-4-(trifluoromethyl)phenyl]methyl]- | [CAS]
2360909-50-6 | [Synonyms]
PD-1-IN-24
L-Serine, 2-methyl-N-[[3-[(1E)-2-(2-methyl[1,1'-biphenyl]-3-yl)ethenyl]-4-(trifluoromethyl)phenyl]methyl]- | [Molecular Formula]
C27H26F3NO3 | [MOL File]
2360909-50-6.mol | [Molecular Weight]
469.5 |
| Chemical Properties | Back Directory | [Boiling point ]
610.7±55.0 °C(Predicted) | [density ]
1.265±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, sealed storage, away from moisture and light | [solubility ]
DMSO : 100 mg/mL (212.99 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
2.15±0.15(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor[1].
PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) exhibits TGI(%) of 19.96% in the subcutaneous 4T1 murine breast cancer model in BALB/c mice[1].PD-1-IN-24 (compound 1, 15mg/kg, PO, BID) dose-dependently inhibits tumor growth in the Bl6F10 models with TGI% of 35.59% (30 mg/kg), 38.87% (60 mg/kg) and 47.35% (120 mg/kg), respectively[1]. | [References]
[1]. Wang, Yuguang, et al. Combination of small molecule inhibitor of the PD-1/PD-L1 interaction and anti-PD-1 antibody for treatment of cancer. Patent WO 2021052386. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|